Protease nexin-1 expression is altered in human breast cancer

Cancer Cell International

Volumn 6, Issue , 2006, Pages

  Candia, Britny J ^a   Hines, William Curt ^a   Heaphy, Christopher M ^a   Griffith, Jeffrey K ^a   Orlando, Robert A ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE NEXIN I; UROKINASE;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CARCINOGENESIS; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLOTS AND CURVES; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR CELL;

EID: 33746085972     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-6-16     Document Type: Article

References (37)

1. Price JT, Bonovich MT, Kohn EC: The biochemistry of cancer dissemination. Critical Reviews in Biochemistry & Molecular Biology 1997, 32(3):175-253.
2. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR: Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999, 107(1):120-127.
3. Carroll VA, Binder BR: The role of the plasminogen activation system in cancer. Seminars in Thrombosis & Hemostasis 1999, 25(2):183-197.
4. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular & Molecular Life Sciences 2000, 57(1):25-40.
5. Ellis V, Scully MF, Kakkar VV: Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. Journal of Biological Chemistry 1989, 264(4):2185-2188.
6. Pepper MS: Extracellular proteolysis and angiogenesis. Thrombosis & Haemostasis 2001, 86:346-355.
7. Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Research 1991, 51(18 Suppl):5054s-5059s.
8. Knoop A, Andreasen PA, Andersen JA, Hansen S. Laenkholm AV, Simonsen AC, Andersen J, Overgaard J, Rose C: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. British Journal of Cancer 1998, 77(6):932-940.
9. Stephens RW, Brunner N, Janicke F, Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Research & Treatment 1998, 52(1-3):99-111.
10. Collen D: The plasminogen (fibronolytic) system. Thrombosis & Haemostasis 1999, 82:259-270.
11. Knauer DJ, Thompson JA, Cunningham DD: Protease nexins: cell-secreted proteins that mediate the binding, internalization, and degradation of regulatory serine proteases. J Cell Physiol 1983, 117(3):385-396.
12. Kim NK, Chio MJ, Chung HM, Sohn TJ, Hwang SG, Oh D, Lee HH, Lee YH, Ko JJ: Increased expression and localization of a serine protease inhibitor, protease nexin-1 (PN-1), in the ovary and uterus during implantation in rat. Thrombosis Research 2001, 103 (2):135-142.
13. Kruithof EK: Plasminogen activator inhibitors - a review. Enzyme 1988, 40(2-3):113-121.
14. Stone SR, Nick H, Hofsteenge J, Monard D: Glial-derived neurite-promoting factor is a slow-binding inhibitor of trypsin, thrombin, and urokinase. Archives of Biochemistry & Biophysics 1987, 252(1):237-244.
15. Vaughan PJ, Cunningham DD: Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors. Journal of Biological Chemistry 1993, 268(5):3720-3727.
16. Houenou LJ, Turner PL, Li L, Oppenheim RW, Festoff BW: A serine protease inhibitor, protease nexin 1, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(3):895-899.
17. Zurn AD, Nick H, Monard D: A glia-derived nexin promotes neurite outgrowth in cultured chick sympathetic neurons. Developmental Neuroscience 1988, 10(1):17-24.
18. Festoff BW, Smirnova IV, Ma J, Citron BA: Thrombin, its receptor and protease nexin 1, its potent serpin, in the nervous system. Seminars in Thrombosis & Hemostasis 1996, 22(3):267-271.
19. Lindner J, Zinser G, Werz W, Goridis C, Bizzini B, Schachner M: Experimental modification of postnatal cerebellar granule cell migration in vitro. Brain Research 1986, 377(2):298-304.
20. Donovan FM, Vaughan PJ, Cunningham DD: Regulation of protease nexin-1 target protease specificity by collagen type IV. Journal of Biological Chemistry 1994, 269(25):17199-17205.
21. Castello R, Estelles A, Vazquez C, Falco C, Espana F, Almenar SM, Fuster C, Aznar J: Quantitative real-time reverse transcription-PCR assay for urokinase activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expression in primary breast cancer. Clinical Chemistry 2002, 48(8):1288-1295.
22. Howard EW, Knauer DJ: Biosynthesis of Protease Nexin 1. Journal of Biological Chemistry 1986:14184-14190.
23. Scott RWBJB: Purification of human protease nexin. Journal of Biological Chemistry 1983, 258:10439-10444.
24. Harbeck N, Alt U, Berger U, Kruger A, Thomssen C, Janicke F, Hofler H, Kates RE, Schmitt M: Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor I, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clinical Cancer Research 2001, 7(9):2757-2764.
25. Harbeck N, Kruger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Janicke F: Clinical relevance of the plasminogen activator inhibitor type 1 - a multifaceted proteolytic factor. Onkologie 2001, 24(3):238-244.
26. Look MP: Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients. EORTC Receptor and Biomarker Study Group. International Journal of Biological Markers 2000, 15(1):70-72.
27. Lacroix MLG: Relevance of breast cancer cell lines as models for breast tumours: an update. In Breast Cancer Research and Treatment Volume 83. Kluwer Academic Publishers; 2004:249-289.
28. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA: Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis. Thromb Haemost 2004, 91(3):438-449.
29. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003, 9(19):1545-1564.
30. Duffy MJ: The urokinase plasminogen activator system: role in malignancy. Current pharmaceutical design 2004, 10(1):39-49.
31. Buchholz M, Biebl A, Neebetae A, Wagner M, Iwamura T, Leder G, Adler G, Gress TM: SERPINE2 (protease nexin 1) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Research 2003, 63(16):4945-4951.
32. Chorostowska-Wynimko J, Skrzypczak-Jankun E. Jankun J: Plasminogen activator inhibitor type-I: its structure, biological activity and role in tumorigenesis (Review). International Journal of molecular medicine 2004, 13(6):759-766.
33. Cunningham DD: Regulation of neuronal cells and astrocytes by protease nexin-1 and thrombin. Annals of the New York Academy of Sciences 1992:228-236.
34. Monard D: Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends in neurosciences 1988, 11(12):541-544.
35. Rossignol P, Ho-Tin-Noe B, Vranckx R, Bouton MC, Meilhac O, Lijnen HR, Guillin MC, Michel JB, Angles-Cano E: Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J Biol Chem 2004, 279(11):10346-10356.
36. Wiseman BS, Werb Z: Stromal effects on mammary gland development and breast cancer. Science 2002, 296(5570):1046-1049.
37. Baker JB, Low DA, Simmer RL, Cunningham DD: Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980, 21(1):37-45.